Type 1

This information sheet briefly explains the cause, effects, and management of Spinal Muscular Atrophy (SMA) Type 1. It includes sources of further information and support. It is for the families of children diagnosed with SMA Type 1. It may also be useful for healthcare and other professionals.

SMA Type 1 is a complex condition; there is a lot of information to take in, and every child with SMA is different. Your child’s medical team will always be happy to go over any of this with you.

What is Spinal Muscular Atrophy?

Spinal Muscular Atrophy (SMA) is a rare, genetically inheritedneuromuscular condition. SMA may affect crawling and walking ability, arm, hand, head and neck movement, breathing and swallowing. SMA is often grouped into ‘Types’. Types of SMA are based on the age at which symptoms first appear and what physical ‘milestones’ a baby or child is likely to achieve. Milestones can include the ability sit, stand, or walk.

There are four main types of SMA: Types 1, 2 and 3 appear in childhood. Type 4 appears in adulthood and is also known as Adult Onset SMA.

These ‘Types’ are not rigid categories. There is a wide spectrum of severity between the different types of SMA and between children, young people, and adults within each type.

There are also other, even rarer, forms of SMA with different genetic causes including SMA with Respiratory Distress (SMARD), Spinaland Bulbar Muscular Atrophy (SBMA), and Distal SMA (DSMA).

What causes SMA?

Usually, electrical signals from our brain are sent down our spinalcord along our nerve cells and through to our muscles. This makes it possible for us to consciously contract our muscles and to make them move.

SMA affects a particular set of nerve cells called the lower motor neurones1 which run from the spinal cord out to our muscles. The lower motor neurones carry messages that make it possible for us to move the muscles we use to crawl and walk, to move our arms, hands, head, and neck, and to breathe and swallow.

For our lower motor neurones to be healthy, we need to produce an important protein called the Survival Motor Neuron (SMN) protein. Our ability to do this is controlled by a gene called Survival MotorNeuron 1 (SMN1)2.

We all have two copies of this SMN1 gene, one from each parent. People who have two faulty copies of the SMN1 gene have SMA. People who have one faulty copy of the SMN1 gene are carriers of SMA. Carriers do not have SMA or any symptoms of SMA.  People who have two healthy copies of the SMN1 gene do not have SMA and are not carriers.

SMA is passed from parents to their children through their SMN1genes. When two people who are carriers have a child together, their child may inherit two faulty SMN1 genes, one from each parent. If this happens, then their child will have SMA.

Having two faulty SMN1 genes means that a child is only able to produce very low amounts of the SMN protein. This causes their lower motor neurones in their spinal cord to deteriorate. Messages from their spinal cord do not efficiently get through to their muscles, which makes movement difficult. Their muscles waste due to lack of use and this is known as muscular atrophy.

What is SMA Type 1?

SMA Type 1 is the most severe form of SMA. It accounts for between 50 – 70% of cases of childhood onset SMA. It is sometimes called Werdnig-Hoffman Disease or severe infantile SMA.

Each baby with SMA Type 1 is different. The symptoms of SMA Type 1 usually appear within the first few months of life. In some cases SMA can affect babies even before birth and mothers may remember that their baby had become less active towards the end of their pregnancy. Generally, the earlier the onset of symptoms, the more severe the condition. The most severely affected babies may die before, during, or very shortly after birth. This is sometimes referred to as SMA Type 0.

Sometimes doctors try to indicate the degree of severity within SMA Type 2 by using a decimal classification3, for example, 1.1, 1.2, 1.5, 1.9. If you have any queries regarding this please speak to your child’s medical team.

SMA Type 1 is a life-limiting condition. Though it is not possible to accurately predict, for the majority of children (approximately 95%) life expectancy is less than 18 months. In general babies diagnosed within the first few weeks or months of life have a significantly shorter life expectancy.

How is SMA Type 1 diagnosed?

If a doctor suspects SMA after taking a medical history and physically examining a baby, the diagnosis is confirmed by taking a blood sample for DNA testing. The blood sample is tested for a deletion in the survival motor neurone 1 (SMN1) gene on chromosome 5. The result of the test is usually available within 2 – 4 weeks.

Further tests, such as an electromyogram (EMG) or muscle biopsy, may be considered if there is any uncertainty about the diagnosis, but are not usually needed to confirm SMA.

What are the effects of SMA Type 1?

Babies with SMA Type 1 are often described as ‘floppy’ babies, due to their low muscle tone (hypotonia) and severe muscle weakness. The muscle weakness affects movement, swallowing and breathing. Babies with SMA Type 1 are unable to lift their heads, have difficulty rolling over and are unable to sit unsupported. They may also have a weak cry.

In SMA, muscle weakness is usually symmetrical. The muscles close to the centre of the body (proximal muscles) are usually affected more severely than the muscles situated away from the centre of the body (distal muscles) and the legs are generally weaker than the arms. This results in babies having difficulty lifting their arms and legs, while still being able to use their hands and fingers.

The brain is unaffected and babies affected by SMA are often described as bright, alert and responsive. The muscles of the face are not usually affected so babies can smile and frown.

Weakness of the respiratory muscles can cause severe difficulties with breathing and coughing. It can also increase susceptibility torespiratory viruses and infections which can be life-threatening.

The muscles used for sucking and swallowing are also affected and this may cause difficulty with feeding and weight gain. Difficulty with swallowing can increase the risk of fluids, or food, passing into the lungs (aspiration) which can cause choking and, in some cases,pneumonia.

Is there a treatment or cure?

At present there is no cure for SMA, and no treatment that will repair the damage to the lower motor neurones or reverse the weakening of the muscles. However there is a range of options aimed at managing symptoms, reducing complications of weakness and maintaining the best quality of life for as long as possible.

A baby with SMA Type 1 should receive care from a multidisciplinary team which may include specialists in neuromuscular conditions,palliative care, respiratory medicine, physiotherapy, occupational therapy, speech and language therapy, dietetics and a hospital or community consultant paediatrician. Where available, a keyworker should assist in the co-ordination of services for the family.

The impact of a diagnosis of SMA Type 1 on families is enormous. Parents should be offered ongoing support with emotional, practical and financial issues following the diagnosis of their baby (see section ‘What other help is available’).

Parents should also be offered a referral for genetic counselling to help understand how SMA is passed on and the chances of other children being affected. Genetic counselling also provides the opportunity to discuss choices for future pregnancies.

Support with breathing

Good respiratory management is important to provide comfort and reduce complications of muscle weakness. An overview of respiratorymanagement in SMA can be found in the booklet ‘Standards of Care for Spinal Muscular Atrophy – the family guide’ published by TREAT-NMD. This booklet can be obtained from Spinal Muscular AtrophySupport UK or downloaded from the TREAT-NMD website.

There are a number of options for respiratory support. Not all options will be appropriate for all babies with SMA Type 1.

The options may include:

Choosing the most appropriate management involves very difficult decisions. Parents should have time and support to ask questions and discuss the different options, to help decide which is most appropriate for their baby. These discussions will be with the medical team who has knowledge of their baby’s condition and possible progression. Parents may also wish to seek emotional support from sources outside the medical team e.g. their family, community and spiritual leaders.

Support with feeding and swallowing

Babies with SMA Type 1 may encounter problems with feeding and swallowing due to muscle weakness. Feeding can become a tiring process for babies with SMA Type 1 and as a result they may lose weight. Babies with a weak swallow are also at risk of inhaling (aspirating) their feed which can cause chest infections.

Advice and support on feeding, swallowing and diet is available to parents from a number of healthcare professionals. These may include the health visitor at their local health centre, the child’s consultant, speech and language therapist, dietitian and community nurse. Occupational therapists and physiotherapists may also advise on positioning and seating which may assist feeding.

At this time there is no clear evidence that babies with SMA Type 1 need a therapeutic feed or one with an increase or decrease in particular nutrients.

If swallowing becomes unsafe, or if a baby is not gaining enough weight, alternative ways of feeding may be suggested. These may include feeding through a nasogastric (NG) tube, a nasojejunal (NJ) tube or a gastrostomy (G) tube.

Parents should have the opportunity to discuss the reasons for these suggestions and have time to ask questions, so they understand the possible benefits and risks to their baby. Whichever option is chosen, parents will be provided with training and support to enable them to feed their child safely at home.

Constipation is a common problem with babies with SMA Type 1. It can cause discomfort and respiratory distress. Some babies may also experience reflux. To reduce discomfort and prevent complications, the management of these symptoms should be discussed with the baby’s medical team.

Options for care and support

Parents should have the opportunity to discuss the range of care options in depth with their baby’s medical team to decide what support is most appropriate for their individual circumstances. These discussions are important for developing an anticipatory care plan, which records the treatment parents wish their baby to receive when his/her health deteriorates or in an emergency situation. This plan can be reviewed and parents can change their minds at any time.

Ideally the goal of care is to enable a child to enjoy a good quality of life at home with their family for as long as possible, with a minimum of hospital admissions.

In addition to medical interventions available for breathing and feeding, additional support is available to improve a baby’s health and wellbeing and to provide emotional support for the family. When a baby is at home this may be provided by their GP, community nursing or palliative care team. Children’s hospices also offer a wide range of services and support to children with life-limiting conditions and their families throughout the UK. Details of local children’s hospice andpalliative care services are available from ‘Together for Short Lives’.  Helpline: 0808 8088 100.

Physiotherapy can provide passive exercises to enable movement that babies are unable to make independently. Parents can be taught these techniques so they can enjoy doing these with their baby at home between appointments. Passive exercises are also good for babies’ circulation and help prevent stiffening of the joints (contractures).

Physiotherapists may suggest performing stretches and exercises when a baby is in the bath, swimming or hydrotherapy pool. Building these exercises into play can make them fun and babies enjoy the additional freedom of movement provided by warm water.

Chest physiotherapy is also very important to help clear the chest when babies have difficulty coughing.

Good posture management can improve comfort. An occupational therapist can advise on seating which will help to provide appropriate support for babies with low muscle tone. This will also make it easier for them to play.

Sleep systems may sometimes be provided to increase comfort and support a baby’s limbs in a good position at night time.

What other help is available?

In addition to the care and support provided by a child’s medical team, Spinal Muscular Atrophy Support UK’s Support Services team can provide information and support to families in the UK affected by SMA. Our Outreach Workers are able to visit families whose baby has been diagnosed with SMA Type 1. They offer personalised support and information, and are available to answer questions. They can help families understand SMA and can discuss the support they may be entitled to. We can put families in touch with one of our Peer Support Volunteers who has personal experience of living with SMA Type 1. Multisensory toy packs are available for babies diagnosed with SMA Type 1 in the UK.

Information about these services is available on our website or please contact us on 01789 267520 or email[email protected]

The Muscular Dystrophy Campaign (MDC) provides information and assistance, including grants towards specialist equipment, for people affected by a range of neuromuscular conditions. Visit their websitehere.

Details of the network of Regional Care Advisers attached to NHSneuromuscular clinics in various regions of the UK are available on the MDC’s website.

Families living in the United Kingdom may be eligible for a number of financial benefits to help towards the cost of providing the extra care their child may need, depending on individual circumstances.

For further information about financial benefits, visit the Gov.UKwebsite (see sections ‘Benefits’ and ‘Carers and Disability Benefits’).

The family’s Health Visitor, Community Nurse, Neuromuscular Care Advisor, Family Support Worker or Social Worker may be able to assist with applications for financial benefits.

In addition to statutory welfare benefits, there are also a number of charities that may assist with the cost of general household goods, specialist equipment and holidays / days out. SMA Support UK has more information on these possibilities.

What does the future hold?

Research is advancing in many areas. To find out more about SMA research, go to our research pages.

The UK SMA Patient Registry is a database of genetic and clinicalinformation about people affected by SMA.  Promising new treatments for SMA are being developed. These need to be tested inclinical trials but because SMA is a rare condition it can sometimes take years to find enough patients for a clinical trial. The SMA Patient Registry can speed this up.

The Registry also helps specialists gain more knowledge about the condition and the number of people affected by SMA. This information helps to develop and improve worldwide standards of care for people with SMA.

You can find out more by contacting [email protected] or phone: 0191 2418617.

 

Author: Hilary Adams SMA Support UK Information and Support Co-ordinator

Version: 2.3. Last reviewed: October 2013. Next review date: October 2015.

 

References

  1. Lunn, M.R. and Wang, C.H. (2008) ‘Spinal muscular atrophy’,The Lancet, 371(9630), pp. 2120-2133.
  2. Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., Le Paslier, D., Frézal, J., Cohen, D., Weissenbach, J., Munnich, A. and Melki, J. (1995) ‘Identification and characterization of aspinal muscular atrophy-determining gene’, Cell, 80(1), pp. 155-165.
  3. Dubowitz, V. (1999) ‘Very severe spinal muscular atrophy (SMA Type 0): an expanding clinical phenotype’, European Journal Paediatric Neurology, 3(2), pp. 49-51.
  4. Commission of the European Communities (2008)Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee to the Regions on Rare Diseases: Europe’s challenges. Available here.

Other sources used:

K.Swoboda, J.Kissel, T.Crawford, M.Bromberg, G.Acsadi, G.D’Anjou, K.Krosschell, S.Reyna, M.Schroth, C.Scott, L.Simard, Perspectives on clinical trials in spinal muscularatrophy  J Child Neurol 2007 22:957-966

K.Aton, R.Hurst Davis, K.C.Jordan, C.B.Scott, K.J.Swoboda,Vitamin D intake in spinal muscular atrophy type 1 cohort: correlations with bone health J Child Neurol published online 17th January 2013

A.Nadeau, G.D’Anjou, G.Debray, Y.Robitaille, L.Simard and M.Vanasse,  A newborn with Spinal Muscular Atrophy Type 0 presenting with a clinicopathological picture suggestive of myotubular myopathy J Child Neurol 2007 22:1301

H.Roper, R.Quinlivan on behalf of workshop participants,Implementation of “the consensus statement for the standard of care in spinal muscular atrophy” when applied to infants with severe type 1 SMA in the UK Arch Dis Child 2010 95:845-849

TREAT-NMD Neuromuscular Network, Standards of Care forSpinal Muscular Atrophy 2008 www.treat-nmd.eu/care/sma/family-guide

M.Chatwin, A.Bush, A.K.Simonds, Outcome of goal-directed non-invasive ventilation and mechanical insufflation/exsufflation in spinal muscular atrophy Arch Dis Child 2011 96:426-432

C.H.Wang, R.S.Finkel, E.S.Bertini, M.Schroth, A.Simonds, B.Wong, A.Aloysius, L.Morrison, M.Main, M.A.Thomas, T.O.Crawford, A.Trela and participants of the International Conference on SMA Standard of Care, Consensus statement for Standard of Care in Spinal Muscular Atrophy J Child Neurol 2007 22:1027-1049

A.Bush, J.Fraser, E.Jardine, J.Paton, A.Simonds, C.Wallis,Respiratory management of the infant with type 1 spinalmuscular atrophy Arch Dis Child 2005 90:709-711